CancerIQ

CancerIQ operates within the specialized field of precision cancer prevention, offering a platform designed to assist healthcare providers in identifying, evaluating, and managing patients who are at a heightened risk for hereditary cancer. The company was co-founded in 2013 by Olufunmilayo I. Olopade, MD, a distinguished oncologist and expert in cancer genetics, and her daughter, Feyi Olopade Ayodele, who serves as the CEO. The inception of the company is rooted in Dr. Olopade's extensive clinical and research experience at the University of Chicago, where she recognized the critical gap between genetic discoveries and their practical application in patient care.

Feyi Olopade Ayodele brings a complementary background in business and finance to the company. Holding an MBA from The Wharton School, her expertise has been instrumental in navigating the complex healthcare market and scaling the company's operations. This mother-daughter partnership combines deep clinical and genetic knowledge with strategic business acumen, directly addressing the challenge of integrating genetic risk assessment into routine clinical workflow.

The company's core offering is a software platform that automates the process of identifying at-risk patients through screening questionnaires, pedigree analysis, and the integration of genetic test results. This system streamlines what is traditionally a time-consuming and manual process, allowing clinicians to more efficiently determine who may benefit from genetic counseling and testing. The platform serves a diverse client base, including hospitals, cancer centers, and women's health clinics. CancerIQ's business model is primarily based on a subscription-based software-as-a-service (SaaS) model, where healthcare organizations pay for access to the platform to manage their high-risk patient populations effectively.

By providing tools that support early detection and preventative care, CancerIQ aims to shift the paradigm from reactive cancer treatment to proactive cancer risk management. The platform facilitates guideline-based care, helping providers to create personalized care plans for high-risk individuals, which may include increased surveillance, risk-reducing medications, or preventative surgeries. The company has secured multiple rounds of funding, including a notable $14 million Series B financing round, to expand its technology and market reach.

Keywords: precision prevention, genetic risk assessment, oncology software, high-risk patient management, clinical workflow automation, hereditary cancer, cancer screening, healthcare SaaS, genetic counseling support, population health